Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | ITK | Q08881 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 10/20 | 0.43 |
| ▸ | MAP3K8 | P41279 | 2/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | BCL6 | P41182 | 2/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19527785 | 0.86 | NPC1 (0.47) | EGFRITKSYKMAP3K8CDK4 | |
| SCHEMBL20752084 | 0.80 | EGFR (0.47) | EGFRITKSYKBCL6NCOR2 | |
| SCHEMBL15321362 | 0.75 | EGFR (0.41) | EGFRITKBCL6 | |
| SCHEMBL15321364 | 0.75 | EGFR (0.41) | EGFRITKBCL6 | |
| SCHEMBL19527678 | 0.75 | NPC1 (0.47) | EGFRSYK | |
| SCHEMBL20752248 | 0.73 | LRRK2 (0.49) | SYK | |
| SCHEMBL15769550 | 0.72 | EGFR (0.40) | EGFRSYKBCL6 | |
| SCHEMBL19527732 | 0.71 | NPC1 (0.49) | EGFRSYKBCL6 | |
| SCHEMBL20927131 | 0.70 | EGFR (0.63) | EGFRITKSYK | |
| SCHEMBL655595 | 0.70 | SYK (0.64) | ITKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
| EP-2833889-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9682976-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | PRKCH, PRKCA, PRKCB | EGFR 2299/4885ITK 884/4885SYK 600/4885 |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | EGFR 2299/4885ITK 884/4885SYK 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.